Publications by authors named "Karsten Lindhardt"

Claim this Profile
S
Standardization of In Vitro Testing During Development of Abuse-Deterrent Opioids: Highlights From the Second and Third Category 1 Focus Group Meetings.
Torben Elhauge, Sebastian Schwier, Stephen W Hoag, Beatrice Setnik, Robert Bianchi, Karsten Lindhardt

Pain Pract· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
Jeffrey M Dayno, Gwendolyn Niebler, John Lawler, Torben Elhauge, Karsten Lindhardt

J Opioid Manag· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery.
Nikolaj Skak, Torben Elhauge, Jeffrey M Dayno, Karsten Lindhardt

J Opioid Manag· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.
Lynn R Webster, Michael D Smith, John Lawler, Karsten Lindhardt, Jeffrey M Dayno

Pain Med· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.
Michael D Smith, Lynn R Webster, John Lawler, Karsten Lindhardt, Jeffrey M Dayno

Pain Med· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ALERRT instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.
Edward J Cone, August R Buchhalter, Karsten Lindhardt, Torben Elhauge, Jeffrey M Dayno

Am J Drug Alcohol Abuse· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Striving for Consensus on Approaches to Category 1 Testing of Abuse-Deterrent Formulations of Opioids: Discussions from the First Category 1 Focus Group Meeting.
Edward J Cone, Marta Sokolowska, Karsten Lindhardt

Pain Pract· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poster 416 Dissolution Studies in the Presence of Alcohol with an Abuse-Deterrent, Extended-Release Morphine Product Candidate.
Torben Elhauge, Lene Kristensen, Jeffrey M Dayno, Karsten Lindhardt

PM R· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poster 420 Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users.
Michael D Smith, Lynn R Webster, John Lawler, Karsten Lindhardt, Jeffrey M Dayno

PM R· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users.
Lynn R Webster, Michael D Smith, John Lawler, Karsten Lindhardt, Jeffrey M Dayno

PM R· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poster 457 Bioequivalence and Food Effect of a Novel, Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate Compared with a Currently Available Non-AD, ER Morphine Product.
Jeffrey M Dayno, John Lawler, Gwendolyn Niebler, Karsten Lindhardt

PM R· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium glycocholate transport across Caco-2 cell monolayers, and the enhancement of mannitol transport relative to transepithelial electrical resistance.
Karsten Lindhardt, Erik Bechgaard

Int J Pharm· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal bioavailability of diazepam in sheep correlated to rabbit and man.
Karsten Lindhardt, David R Olafsson, Sveinbjörn Gizurarson, Erik Bechgaard

Int J Pharm· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis